StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Xalkori (crizotinib) [legacy through FY23] by Quarter

Xalkori (crizotinib) [legacy through FY23] ($M) ($M)

QuarterlyAnnual

Pfizer Xalkori (crizotinib) [legacy through FY23]: $91M in Q4 2023, down 11.7% from a year earlier. No newer figure appears in the documents we track.

Latest, Q4 2023
91
Period ended Dec 31, 2023
Change on a year earlier
-11.7%
103 in Q4 2022
History
24 quarters
Since Q1 2018
Sources
19
Documents cited below

Where the Q4 2023 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2024-02-22) ↗

Reported in Form 10-K Segment Note.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedXalkori (crizotinib) [legacy through FY23] ($M) ($M)Year on yearSource
Q4 2023Dec 31, 202391-11.7%Form 10-K (filed 2024-02-22) ↗
Q3 2023Oct 1, 202386-27.1%Form 10-Q (filed 2023-11-08) ↗
Q2 2023Jul 2, 202386-27.1%Form 10-Q (filed 2023-08-09) ↗
Q1 2023Apr 2, 2023111-12.6%Form 10-Q (filed 2023-05-10) ↗
Q4 2022Dec 31, 2022103-15.6%Form 10-K (filed 2024-02-22) ↗
Q3 2022Oct 2, 2022118+1.7%Form 10-Q (filed 2023-11-08) ↗
Q2 2022Jul 3, 2022118-1.7%Form 10-Q (filed 2023-08-09) ↗
Q1 2022Apr 3, 2022127-5.2%Form 10-Q (filed 2023-05-10) ↗
Q4 2021Dec 31, 2021122-9.6%Form 10-K (filed 2024-02-22) ↗
Q3 2021Oct 3, 2021116-4.9%Form 10-Q (filed 2022-11-09) ↗
Q2 2021Jul 4, 2021120-13.0%Form 10-Q (filed 2022-08-10) ↗
Q1 2021Apr 4, 2021134-10.1%Form 10-Q (filed 2022-05-11) ↗
Q4 2020Dec 31, 2020135-6.9%Form 10-K (filed 2023-02-23) ↗
Q3 2020Sep 27, 2020122-6.2%Form 10-Q (filed 2021-11-12) ↗
Q2 2020Jun 28, 2020138+3.8%Form 10-Q (filed 2021-08-12) ↗
Q1 2020Mar 29, 2020149+21.1%Form 10-Q (filed 2021-05-13) ↗

Cite this data

StockData. (2026). Pfizer Xalkori (crizotinib) [legacy through FY23] ($M), quarterly Q1 2018–Q4 2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/xalkori-leg

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.